Whalesbook
Torrent Pharmaceuticals saw its revenue climb significantly in the fourth quarter of FY26, boosted by strong sales in India and key international markets like Brazil and the United States. Despite this revenue growth, the company's net profit declined year-on-year.
Margin Pressure Hits Profitability
For the fourth quarter ending March 31, 2026, Torrent Pharma posted a net profit of ₹389 crore, a 21.9% decrease from ₹498 crore in the same period last year. Revenue, however, surged 41.8% to ₹4,197 crore. While Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 40.7% to ₹1,356 crore, the EBITDA margin narrowed slightly to 32% from 33% a year earlier. This marginal dip indicates rising operational costs or pricing challenges, which could be a concern as the company prepares for a large capital raise. The company's stock closed at ₹4,494.00 on the BSE, up 0.52% for the day.
Strong Performance Across Key Markets
The company's domestic business was a major driver, with revenues increasing by 43% to ₹2,215 crore, far exceeding the Indian Pharmaceutical Market's 10% growth. Torrent's base business grew 15%, and its new Gx Semaglutide product captured 38% market share. In international markets, Brazil's revenue rose 30% to ₹455 crore, and the United States market saw a 31% increase to ₹396 crore with new product launches. Germany's revenue grew 16% to ₹333 crore, though constant currency revenues slightly decreased due to supply chain issues.
For the full fiscal year 2026, Torrent Pharma's total revenue was ₹15,733 crore, with net profit at ₹1,556 crore, an 11.4% decrease from the previous year.
Capital Raise and Shareholder Returns
Torrent Pharmaceuticals is seeking shareholder approval for a Qualified Institutional Placement (QIP) to raise up to ₹5,000 crore. These funds are earmarked for future expansion and strategic initiatives. The company also proposed a final dividend of ₹9 per equity share for FY26, adding to an interim dividend of ₹29 per share. The capital raise signals ambitious growth plans but prompts questions about the necessity of external funding given current revenue performance.
Risks and Competitive Landscape
The slight reduction in EBITDA margins, despite strong revenue growth, remains a key risk, suggesting potential challenges in cost management or pricing power. The proposed ₹5,000 crore QIP also carries the risk of shareholder dilution. Competitors like Sun Pharmaceutical Industries and Cipla, while also showing strong growth, typically maintain higher EBITDA margins, around 20-25% in recent quarters. This comparison highlights potential sector-specific pressures or internal cost challenges for Torrent Pharma, which could impact the long-term value of the QIP.
Future Outlook
Torrent Pharmaceuticals' diverse market presence and product pipeline, including the successful launch of Gx Semaglutide, position it for continued revenue growth. However, improving profit margins will be critical for increasing shareholder value. The company's ability to manage operational costs effectively and integrate new products in a competitive market will be closely watched by analysts.